Cardiovascular status of breast cancer patients before and after receiving anthracycline chemotherapy regimen

FCS8829, a 4-page fact sheet by Martha C. Monroe and Barbara F. Shea, is intended for breast cancer patients who are preparing for their lumpectomy or mastectomy surgery. It helps patients understand what to expect before and after surgery. Includes information on understanding medical procedures and coping physically and psychologically. Also features quotes and experiences from other breast cancer patients. Published by the UF Department of Family, Youth and Community Sciences, April 2007.

Download Full-text

Neural Correlates and Functional Cognitive Maps in Breast Cancer Survivors Receiving Different Chemotherapy Regimens; a QEEG/HEG-based Investigation

10.1101/2021.08.28.21262758 ◽

2021 ◽

Author(s):

Maryam Vasaghi Gharamaleki ◽

Seyedeh Zahra Mousavi ◽

Maryam Owrangi ◽

Mohammad Javad Gholamzadeh ◽

Ali-Mohammad Kamali ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Breast Cancer Survivors ◽

Near Infrared ◽

Chemotherapy Regimen ◽

Current Source ◽

Control Group ◽

Breast Cancer Patients ◽

Cognitive Domains ◽

Clinical Disorder

Background: Post-chemotherapy cognitive impairment commonly known as "chemobrain" or "chemofog" is a well-established clinical disorder affecting various cognitive domains including attention, visuospatial working memory, executive function, etc. Although several studies have confirmed the chemobrain in recent years, scant experiments have evaluated the potential neurotoxicity of different chemotherapy regimens and agents. In this study, we aimed to evaluate the extent of attention deficits, one of the commonly affected cognitive domains, among breast cancer patients treated with different chemotherapy regimens through neuroimaging techniques. Methods: Breast cancer patients treated with two commonly prescribed chemotherapy regimens, AC-T and TAC, and healthy volunteers were recruited. Near-infrared hemoencephalography (nirHEG) and quantitative electroencephalography (qEEG) assessments were recorded for each participant at rest and during task performance to compare the functional cortical changes associated with each chemotherapy regimen. Results: The qEEG analysis revealed increased power of high alpha/low beta or sensorimotor rhythm (SMR) frequency in left fronto-centro-parietal regions involved in dorsal and ventral attention networks (DAN and VAN) in the AC-T-treated group comparing to the TAC and control group. The AC-T group also had the highest current source density (CSD) values in DAN and VAN-related centers in 10 and 15 Hz associated with the lowest Z-scored FFT coherence in the mentioned regions. Conclusions: The mentioned findings revealed increased cognitive workload and lack of cognitive ease in breast cancer patients treated with the AC-T regimen proposing the presumable neurotoxic sequelae of this chemotherapy regimen in comparison with the TAC regimen.

Download Full-text

Managing Cancer and Living Meaningfully (CALM) Intervention on Chemotherapy-Related Cognitive Impairment in Breast Cancer Survivors

Integrative Cancer Therapies ◽

10.1177/1534735420938450 ◽

2020 ◽

Vol 19 ◽

pp. 153473542093845

Author(s):

Ke Ding ◽

Xiuqing Zhang ◽

Jingjing Zhao ◽

He Zuo ◽

Ziran Bi ◽

...

Keyword(s):

Breast Cancer ◽

Cognitive Impairment ◽

Psychological Distress ◽

Cognitive Function ◽

Cancer Therapy ◽

Cancer Patients ◽

Functional Assessment ◽

Breast Cancer Survivors ◽

Breast Cancer Patients ◽

Before And After

Objective: To evaluate the effectiveness and feasibility of Managing Cancer and Living Meaningfully (CALM), which is used to reduce chemotherapy-related cognitive impairment (CRCI), relieve psychological distress, and improve quality of life (QOL) in Chinese breast cancer survivors (BCs). Methods: Seventy-four BCs were enrolled in this study. All patients were randomly assigned to either the CALM group or the care as usual (CAU) group. All patients were evaluated by the Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog), Distress Thermometer (DT), and the Functional Assessment of Cancer Therapy–Breast (FACT-B) before and after CALM or CAU application to BCs with CRCI. We compared the differences in all these scores between the CALM group and the control group and analyzed the correlation between cognitive function and QOL. Results: Compared with the CAU group, the performance of the CALM group on the FACT-Cog, DT, and FACT-B showed significant differences before and after CALM ( t = −18.909, −5.180, −32.421, P = .000, .000, .000, respectively). Finally, there was a positive correlation between cognitive function and QOL in breast cancer patients before ( r = 0.579, P = .000) and after ( r = 0.797, P = .000) treatment. Conclusions: The present results indicated that CALM has salutary effects on the improvement of cognitive impairment and QOL and relieves psychological distress in breast cancer patients, which may be due to a positive correlation between psychological distress and cognitive function or QOL.

Download Full-text

Myocardial infarction, ischaemic stroke and pulmonary embolism before and after breast cancer hospitalisation

Thrombosis and Haemostasis ◽

10.1160/th10-12-0778 ◽

2011 ◽

Vol 106 (07) ◽

pp. 149-155 ◽

Cited By ~ 3

Author(s):

Sumitra Shantakumar ◽

Pieter W. Kamphuisen ◽

Fernie J. A. Penning-van Beest ◽

Ron M. C. Herings ◽

Myrthe P. P. van Herk-Sukel

Keyword(s):

Breast Cancer ◽

Myocardial Infarction ◽

Pulmonary Embolism ◽

Ischaemic Stroke ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Increased Risk ◽

Before And After ◽

Receive Treatment ◽

Free Women

SummaryWe studied the occurrence of myocardial infarction (MI), ischaemic stroke (IS) and pulmonary embolism (PE) before and after breast cancer hospitalisation compared with cancer-free controls. For this, women with a first breast cancer hospitalisation during 2000–2007 were selected from the PHARMO Record Linkage System, including drug use and hospitalisations of three million inhabitants in the Netherlands, and matched 1:10 by age to cancer-free women. The occurrence of MI, IS and PE were assessed in the 12 months before and after breast cancer hospitalisation. The study included 11,473 breast cancer patients, with a mean (± SD) age of 59 (± 14) years. Breast cancer patients were two to three times as likely as their cancer-free controls to have had a hospitalisation for PE, MI or IS in the 12 months before diagnosis, though prevalence was <1% in all groups. Breast cancer patients experienced an extreme high risk of PE in the first six months after diag- nosis (hazard ratio [HR] 23.5, 95% confidence interval [CI] 11.1–49.7 compared to controls), which declined gradually to a four times increased risk (HR 3.6, 95%CI 2.4–5.5) more than 12 months after breast cancer hospitalisation. However, incidence was low: less than five events per 1,000 person years during all time periods. For MI and IS we did not observe significant increased HRs after breast cancer hospitalisation compared to controls. Breast cancer patients seem to have a higher risk profile to develop MI and IS, and receive treatment that increases the risk of PE compared to cancer-free controls, although the frequency of hospitalisations was low.

Download Full-text

Prognostic value of the systemic inflammation response index (SIRI) before and after surgery in operable breast cancer patients

Cancer Biomarkers ◽

10.3233/cbm-201682 ◽

2020 ◽

pp. 1-11

Author(s):

Lei Wang ◽

Yehui Zhou ◽

Suhua Xia ◽

Linlin Lu ◽

Tiantian Dai ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Systemic Inflammation ◽

Prognostic Value ◽

Operable Breast Cancer ◽

Breast Cancer Patients ◽

Inflammation Response ◽

Response Index ◽

Before And After

Download Full-text

Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy

Physiological Reports ◽

10.14814/phy2.13971 ◽

2019 ◽

Vol 7 (1) ◽

pp. e13971 ◽

Cited By ~ 6

Author(s):

Rhys I. Beaudry ◽

Erin J. Howden ◽

Steve Foulkes ◽

Ashley Bigaran ◽

Piet Claus ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Exercise Intolerance ◽

Breast Cancer Patients ◽

Anthracycline Chemotherapy

Download Full-text

Evaluation of breast cancer patients with genetic risk: Before and after a multidisciplinary heredofamiliar cancer unit implementation

Annals of Oncology ◽

10.1093/annonc/mdw385.13 ◽

2016 ◽

Vol 27 ◽

pp. vi465

Author(s):

M. Lobo ◽

S. Lopez-Tarruella ◽

S. Luque ◽

S. Lizarraga ◽

P. Rincon ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Genetic Risk ◽

Breast Cancer Patients ◽

Before And After

Download Full-text

Identification of differential gene expression related to epirubicin-induced cardiomyopathy in breast cancer patients

Human & Experimental Toxicology ◽

10.1177/0960327119893415 ◽

2019 ◽

Vol 39 (4) ◽

pp. 393-401 ◽

Cited By ~ 1

Author(s):

J Peng ◽

Z Wang ◽

Y Li ◽

D Lv ◽

X Zhao ◽

...

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

Cancer Patients ◽

Enrichment Analysis ◽

Global Gene Expression ◽

Pathway Enrichment Analysis ◽

Breast Cancer Patients ◽

Chlorophyll Metabolism ◽

Pathway Enrichment ◽

Before And After

Background: Epirubicin is a potent chemotherapeutic agent for the treatment of breast cancer. However, it may lead to cardiotoxicity and cardiomyopathy, and no reliable biomarker was available for the early prediction of epirubicin-induced cardiomyopathy. Methods: Global gene expression changes of peripheral blood cells were studied using high-throughput RNA sequencing in three pair-matched breast cancer patients (patients who developed symptomatic cardiomyopathy paired with patients who did not) before and after the full session of epirubicin-based chemotherapy. Functional analysis was conducted using gene ontology and pathway enrichment analysis. Results: We identified 13 significantly differentially expressed genes between patients who developed symptomatic epirubicin-induced cardiomyopathy and their paired control who did not. Among them, the upregulated Bcl-associated X protein was related to “apoptosis,” while the downregulated 5′-aminolevulinate synthase 2 (ALAS2) was related to both “glycine, serine, and threonine metabolism” and “porphyrin and chlorophyll metabolism” in pathway enrichment analysis. Conclusions: ALAS2 and the metabolic pathways which were involved may play an important role in the development of epirubicin-induced cardiomyopathy. ALAS2 may be useful as an early biomarker for epirubicin-induced cardiotoxicity detection.

Download Full-text